Neuren Pharmaceuticals Ltd (ASX:NEU) CEO Jon Pilcher speaks with Proactive following the news that its North America partner Acadia Pharmaceuticals has received US Food and Drug Administration approval of DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients. Acadia expects DAYBUE to be available by the end of April 2023.
#ProactiveInvestors #NeurenPharmaceuticals #asx #USFDA #trofinetide
#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
source